A comparison of 64Cu-labeled bi-terminally PEGylated A20FMDV2 peptides targeting integrin ανβ6
Metrics: PDF 373 views | Full Text 900 views | ?
Truc T. Huynh1,2, Sreeja Sreekumar1, Cedric Mpoy1 and Buck E. Rogers1
1 Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA
2 Department of Chemistry, Washington University, St. Louis, MO, USA
|Buck E. Rogers,||email:||email@example.com|
Keywords: integrin ανβ6; PEGylation; Copper-64; DOTA; PCTA
Abbreviations: DOTA: (S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid); PCTA: (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-4-S-(4-isothiocyanatobenzyl)-3,6,9-triacetic acid); MFU: mean fluorescence unit
Received: November 23, 2021 Accepted: February 07, 2022 Published: February 16, 2022
Expression of epithelial-specific integrin ανβ6 is up-regulated in various aggressive cancers and serves as a prognostic marker. Integrin-targeted PET imaging probes have been successfully developed and tested in the clinic. Radiotracers based on the peptide A20FMDV2 derived from foot-and-mouth disease virus represent specific and selective PET ligands for imaging ανβ6-positive cancers. The present study aims to describe the radiolabeling, in vitro and in vivo evaluation of a bi-terminally PEGylated A20FMDV2 conjugated with DOTA or PCTA for 64Cu radiolabeling. Stability studies showed radiolabeled complexes remained stable up to 24 h in PBS and human serum. In vitro cell assays in CaSki cervical cancer cells and BxPC-3 pancreatic cancer cells confirmed that the peptides displayed high affinity for αvβ6 with Kd values of ~50 nM. Biodistribution studies revealed that [64Cu] Cu-PCTA-(PEG28)2-A20FMDV2 exhibited higher tumor uptake (1.63 ± 0.53 %ID/g in CaSki and 3.86 ± 0.58 %ID/g in BxPC-3 at 1 h) when compared to [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (0.95 ± 0.29 %ID/g in CaSki and 2.12 ± 0.83 %ID/g in BxPC-3 at 1 h) . However, higher tumor uptake was accompanied by increased radioactive uptake in normal organs. Therefore, both peptides are appropriate for imaging ανβ6-positive lesions although further optimization is needed to improve tumor-to-normal-tissue ratios.
Integrins are a class of receptors that play essential roles in mediating cell adhesion, making transmembrane connections to the cytoskeleton, and modulating many intracellular signaling pathways [1, 2]. Because of their diverse functions, integrins have been studied extensively for decades, leading to the design and development of integrin antagonists in the treatment of multiple types of cancers. In recent years, ανβ6 has received much attention where its overexpression has been discovered to promote malignant behavior and tumor progression, resulting in poor prognosis and a striking reduction in survival rates for cancer patients [3–7]. ανβ6 has many regulatory functions in oncogenesis and its interaction with fibronectin and/or activation of TGFβ1 are known to lead to invasion and cancer migration [8, 9]. Increased expression levels of ανβ6 have been shown in various cancers including pancreatic, cervical, non–small cell lung cancer and oral squamous cell carcinoma [10–13].
Several ανβ6-targeting ligands have been identified and used in preclinical therapeutic and imaging studies. Hausner et al. used a 20-mer peptide (NAVPNLRGDLQVLAQKVART; A20FMDV2) that showed preferential binding to ανβ6 . Another 20-mer peptide (RGDLATLRQLAQEDGVVGVR; H2009) isolated from a phage-display peptide library by panning on a lung adenocarcinoma cell line also binds to the restrictively expressed integrin ανβ6 . Kimura et al. demonstrated that highly stable cystine knot peptides have potent and specific integrin ανβ6 binding for cancer detection . The shared sequence of “RGDLXXL” (X represents unspecified amino acid) in the central binding region is key to high binding affinity and good selectivity towards ανβ6 integrin [16, 17]. Phage display libraries confirmed that RGD sequence followed by an LXXL motif is crucial in targeting ανβ6, while having minimal interactions with ανβ3, ανβ5, and αIIbβ3 .
This study focuses on the 20-amino-acid, A20FMDV2, derived from the foot-and-mouth disease virus, which was used as a first-generation radiotracer for targeting ανβ6 in vivo . A20FMDV2 was initially labeled with 18F and showed specific binding to ανβ6 both in in vitro cell assays and in vivo tumor-bearing models [18–20]. Though the initial lead compound A20FMDV2 exhibited good affinity towards integrin ανβ6, in vivo studies in tumor mouse models showed rapid excretion, metabolic breakdown, and unexpected high and persistent levels of radioactivity in non-target organs. To improve the pharmacokinetics of peptides, modifications such as cysteine amino acid substitutions, cyclization, PEGylation and incorporation of non-proteinogenic amino acid substitutes have been introduced [21–23]. Bi-terminal PEGylation of the peptide resulted in favorable in vitro and in vivo behavior concerning ανβ6 cell binding affinity and tumor uptake in mouse models . This led to the first-in-human microdose study to assess the safety and pharmacokinetics of [18F]FBA-(PEG28)2-A20FMDV2 which confirmed the favorable performance of bi-terminally PEGylated peptide for identification of small lesions in primary sites as well as common sites of metastatic diseases .
However, radiolabeling of A20FMDV2 with 64Cu (T1/2 12.7 h, β+ = 17%, β− = 39%, EC = 43%, Emax = 0.656 MeV) would allow for easier radiochemical synthesis compared to 18F and allow for later imaging time points where contrast might be improved. Previous studies have used mono-PEGylated A20FMDV2 conjugated with various chelators and evaluated after radiolabeling with 64Cu [25, 26]. The goal of the present study is to use the optimized bi-terminally PEGylated A20FMDV2 conjugated with either DOTA (S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid) or PCTA (3,6,9,15-tetraazabicyclo[9.3.1] pentadeca-1(15),11,13-triene-4-S-(4-isothiocyanatobenzyl)-3,6,9-triacetic acid) and evaluate these constructs in vitro and in vivo after radiolabeling with 64Cu. We chose to evaluate these two chelators because it is known that DOTA does not form the most kinetically stable complexes with copper and therefore we hypothesized that the PCTA peptide would have a better in vivo profile than the DOTA peptide.
Macrocyclic chelator integrin ανβ6 targetting peptides
Bi-terminally PEGylated A20FMDV2 were custom synthesized and conjugated with DOTA and PCTA (Figure 1) and found to be >93 % pure by HPLC and confirmed by mass spectrometry.
Figure 1: Structures of the ανβ6-targeting ligands investigated herein.
The radiolabeling results of the peptides with 64Cu is shown in Table 1. Radiolabeled products were obtained in high radiochemical purity (>95%) as determined by radio-HPLC and used without further purification. The molar activity of both radiolabeled peptides was 18.5 GBq/μmol. HPLC retention times were 8:05 and 8:37 min for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2, respectively (Supplementary Figure 1). Similarly, radio-TLCs demonstrated more than 95% radiochemical purity (Supplementary Figure 2).
Table 1: Summary of in vitro and in vivo studies for investigated ανβ6-targeting ligands
|64Cu-DOTA conjugate||64Cu-PCTA conjugate|
|Labeling Conditions||45°C for 1 h||80°C for 15 mins|
|Molar Activity (GBq/μmol)||18.5||18.5|
|Human Serum Stability||98.9% at 24 h||100% at 24 h|
|Kd (nM)||62.4 ± 3.7 (CaSki)|
37.6 ± 5.4 (BxPC-3)
|60.4 ± 6.7 (CaSki)|
38.1 ± 4.7 (BxPC-3)
|Bmax (# receptors per cell)||0.75 ± 0.03 × 105 (CaSki)|
1.15 ± 0.10 × 105 (BxPC-3)
|0.73 ± 0.02 × 105 (CaSki)|
1.27 ± 0.02 × 105 (BxPC-3)
|Tumor Uptake at 1 h p.i (%ID/g)||0.95 ± 0.29 (CaSki)|
2.12 ± 0.83 (BxPC-3)
|1.63 ± 0.53 (CaSki)|
3.86 ± 0.58 (BxPC-3)
In vitro stability studies of all radiotracers were assessed by incubating in PBS 1X and human serum. There was less than 4% loss of 64Cu in PBS or human serum observed at 24 h (Supplementary Figure 3).
Flow cytometry (Supplementary Figure 4) confirmed the expression level of integrin ανβ6 on CaSki and BxPC-3 cells with MFUs of 12.4 ± 0.1 and 11.1 ± 0.3 respectively when incubated the ανβ6-positive antibody as compared to the control antibody (0.4 ± 0.1 for CaSki cells and 1.2 ± 0.1 for BxPC-3 cells). Expression values on the SiHa and ME-180 cell lines were 0.4 ± 0.1 and 1.5 ± 0.1, respectively, demonstrating the relatively high expression level on CaSki and BxPC-3 cells.
Cell binding and internalization
Both radiolabeled peptides showed binding to ανβ6–expressing cell lines that were significantly inhibited by blocking with A20FMDV2, demonstrating ανβ6-specific binding (Figure 2). The binding was similar between the two peptides [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 and [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2. The binding of both peptides in CaSki and BxPC-3 cells increased rapidly over a 2-h time frame and then plateaued for subsequent time points. More than 75% of the total bound radioactivity was internalized into the cells. Radiolabeled [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 peptide was internalized into the cells at a steady rate from 4% at 15 mins to 18% at 2 h in CaSki cells and from 5% at 15 mins to 20% at 2 h in BxPC-3 cells. Similar behavior was observed for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in which internalization increased from 4% at 15 mins to 18% at 2 h in CaSki cells, and from 6% at 15 mins to 23% at 2 h in BxPC-3 cells.
Figure 2: Representative binding and internalization curves of radiotracers in vitro in (A) CaSki cell line (B) BxPC-3 cell line. Total bound and internalization levels were shown as percent relative to total radioactivity. Data are presented as triplicates of mean ± SD.
Radioligand saturation binding
Receptor-binding affinity of the radiolabeled peptides to ανβ6 was evaluated on CaSki and BxPC-3 cell lines using a saturation binding assay at 4°C. Binding affinities were investigated by determining the equilibrium dissociation constant (Kd) and the maximum binding capacity (Bmax) of radiolabeled conjugates to integrin ανβ6 -positive cells. Representative saturation binding curves in CaSki and BxPC-3 cell lines are shown in Figure 3. Kd values for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (62.4 ± 3.7 nM) and [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 (60.4 ± 6.7 nM) were similar for CaSki cells and slightly better when evaluated on BxPC-3 cells (37.6 ± 5.4 nM for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and 38.1 ± 4.7 nM for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2). The Bmax was calculated to be about 0.75 × 105 receptors per cell in CaSki cell line, whereas BxPC-3 has a maximum binding capacity of approximately 1.20 × 105 receptors per cell for both radiotracers.
Figure 3: Representative saturation binding curves of radiotracers in (A) CaSki cell line (B) BxPC-3 cell line. Y-axis represents fmol of [64Cu]Cu-labeled bi-terminally PEGylated peptides bound to integrin ανβ6 -positive cells. Data are presented as triplicates of mean ± SD.
Biodistribution of the radiolabeled peptides was studied at 1, 4, and 24 h post-injection. Figure 4 shows the biodistribution of both peptides in mice bearing CaSki xenografts. Both showed rapid blood clearance with only 0.26 ± 0.07 %ID/g for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and 0.53 ± 0.10 %ID/g for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 remaining in the blood at 24 h. Overall accumulation of radioactivity in tumors and non-target organs was higher for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 than [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2. High kidney uptake was observed for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 at 113.58 ± 38.31 %ID/g at 1 h p.i, which decreased to 24.38 ± 6.54 %ID/g at 24 h. On the other hand, high and persistent retention of radioactive uptake in kidney was observed for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2, as evidenced by an accumulation of 42.72 ± 4.03 %ID/g at 1 h p.i followed by a slight decrease to 37.04 ± 10.60 %ID/g at 4 h and remained at 20.99 ± 4.67 %ID/g at 24 h. Despite [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 having higher kidney uptake at the initial time points, both the peptides eventually decreased to similar levels at 24 h.
Figure 4: Biodistribution of 64Cu radiotracers in mice bearing ανβ6-expressing CaSki xenograft tumors (A) Radiotracer uptake of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (B) Radiotracer uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in tumors and selected organs (%ID/g; bars = SD; tumors: n = 4 per time point) (ns: no significant, *p < 0.05, T-test).
Biodistribution profiles in BxPC-3 tumor-bearing mice were similar to those of CaSki (Figure 5). Tumor uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 (3.86 ± 0.58 %ID/g) was higher than that of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (2.12 ± 0.83 %ID/g) at 1 h p.i and exhibited good tumor retention with a slight decrease at the 4 h time point (3.09 ± 0.77 %ID/g) and an uptake of 2.45 ± 0.57 %ID/g at 24 h. Despite showing higher accumulation in normal organs compared to [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2, [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 shows shorter retention of activity in normal organs, as indicated by kidney uptake decreasing from 105.39 ± 13.58 %ID/g at 1 h to 28.65 ± 8.45 %ID/g at 24 h.
Figure 5: Biodistribution of 64Cu radiotracers in mice bearing ανβ6-expressing BxPC-3 xenograft tumors (A) Radiotracer uptake of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (B) Radiotracer uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in tumors and selected organs (%ID/g; bars = SD; tumors: n = 4 per time point) (**p < 0.01, ***p < 0.001, T-test).
Between the two radiolabeled peptides, tumor-to-normal-tissue ratios were generally similar for the two peptides (Supplementary Tables 1 and 2). Despite the fact that [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 has a two-fold higher tumor uptake in vivo, it was compensated by increased radioactive uptake in non-target organs. Blocking studies with unlabeled A20FMDV2 confirmed the specific uptake of the peptides in integrin ανβ6-positive tumors. Injection of excess unlabeled peptide resulted in a statistically significant reduction in binding of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in CaSki tumors at 1 h p.i (0.67 ± 0.26 %ID/g with blocking compared to 1.63 ± 0.53 %ID/g without blocking, p = 0.02). There was a reduction in binding of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2, but this did not reach significance (0.65 ± 0.17 %ID/g with blocking compared to 0.95 ± 0.29 %ID/g without blocking, p = 0.12). In the BxPC-3 tumor mouse model, blocking resulted in significantly reduced uptake of both radiotracers with 0.71 ± 0.16 %ID/g in tumors compared to 2.12 ± 0.83 %ID/g for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (p = 0.005) and 0.75 ± 0.09 %ID/g compared to 3.86 ± 0.58 %ID/g for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 (p < 0.001). Normal organs where significant (p < 0.05) blocking occurred include the lung, kidney, muscle, and heart and indicate expression of ανβ6 in these tissues (Supplementary Tables 3 and 4).
Small animal PET/CT images of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 at 1, 4, and 24 h are shown in Figures 6 and 7. These figures show a representative single slice of the coronal PET/CT images for mice bearing BxPC-3 xenografts. These images show good tumor uptake of both radiolabeled constructs at all three time points that was inhibited by an excess of blocking agent. Images show clearance of the radioactivity from the normal tissues and tumor over time. Image analysis of the tumors shows that SUVmaxs increase from 0.44 ± 0.02 at 1 h to 0.57 ± 0.15 at 4 h to 0.69 ± 0.09 at 24 h for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 due to the more rapid clearance of radioactivity from normal tissue compared to tumors. A similar trend was observed for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 which showed SUVmaxs increasing from 0.46 ± 0.04 at 1 h to 0.54 ± 0.05 at 4 h to 0.74 ± 0.21 at 24 h. In addition, tumor specificity is confirmed as the mice that received blocking agent had significantly smaller SUVs (p < 0.044) compared to the non-blocked mice.
Figure 6: Representative micro-PET/CT co-registration images of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 in athymic nude mice bearing BxPC-3 tumors (n = 3). PET imaging was performed at (A) 1 h, (B) 4 h, (C) 24 h after intravenous injection of 3.7 MBq of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 with or without blocking. White arrows indicate the positions of the tumor xenografts. The scale bar unit is Bq/mL (D) Maximum standared uptake values of imaged tumors (*p < 0.05, T-test).
Figure 7: Representative micro-PET/CT co-registration images of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in athymic nude mice bearing BxPC-3 tumors (n = 3). PET imaging was performed at (A) 1 h, (B) 4 h, (C) 24 h after intravenous injection of 3.7 MBq of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 with or without blocking. White arrows indicate the positions of the tumor xenografts. The scale bar unit is Bq/mL (D) Maximum standard uptake values of imaged tumors (*p < 0.05, **p < 0.01, ***p < 0.001, T-test).
Integrin ανβ6, expressed exclusively in epithelial cells, lends itself to be an excellent molecular target for imaging and therapy as it is not expressed in normal adult epithelia but is expressed under special wound healing conditions and in cancer [3–7]. In fact, overexpression of integrin ανβ6 has been observed in various forms of cancer including those of pancreatic, cervical, non–small cell lung cancer and oral squamous cell carcinoma [10–13]. Previous research has shown the correlation between ανβ6 expression with more aggressive disease, reduced survival rates and increased chance of metastasis. Therefore, the design and development of ανβ6-targeting peptides that can serve as both imaging and therapeutic agents would be valuable. In this regard, the 20-mer peptide, A20FMDV2, has been extensively studied due to its specific binding toward integrin ανβ6 . The lead peptide was optimized and radiolabeled with 18F for imaging with a bi-terminal PEG construct used for first-in-human studies . The purpose of this study was to evaluate A20FMDV2 for radiolabeling with copper for potential imaging or therapy. Previous studies investigated 64Cu labeling, only with mono-PEGylation, which is not optimal [25, 26]. Therefore, this study employed the bi-terminally PEGylated peptide conjugated to DOTA or PCTA for radiolabeling with 64Cu. The two peptides are compared in vitro and in vivo.
All radiotracers were radiolabeled in good radiochemical purity (>95 %) at a molar activity of 18.5 GBq/μmol (0.50 Ci/μmol). The molar activity of the DOTA conjugated peptide is comparable to previously published results by Hu et al. (0.48 Ci/μmol) and Hausner et al. (0.58–0.60 Ci/μmol) despite the additional PEG28 [25, 26]. This indicates that the introduction of another PEG28 does not affect the complexation of 64Cu with DOTA. Labeling of the PCTA peptide at 45°C resulted in 72% labeling; therefore we increased the temperature to 80°C for 15 mins to achieve >95% labeling. It is not clear why higher temperatures are needed as other studies have showed efficient 64Cu-labeling of PCTA conjugates at room temperature [27, 28], while some have used temperatures >60°C [29, 30]. While the in vitro serum stability cannot predict in vivo degradation from the liver and other organs, it can be used as a first screen and showed that both peptides were stable enough to warrant further in vivo investigation.
Similar to Hu et al., more than 75% of bound radioactivity of the two chelates were internalized by 1 h in both CaSki and BxPC-3 cells . While the total amount of bound radioactivity at 1 h was less than 60% observed by Hu et al. for the [64Cu]Cu-DOTA labeled A20FMDV2 peptide, this could be due to the use of different cell lines or the additional PEG28 in our studies . The saturation binding showed good affinity of 30–60 nM for both peptides when evaluated in CaSki or BxPC-3 cells. This is generally lower than the reported 1.73 ± 0.46 nM for [111In]In-DTPA-A20FMDV2, which can be due to the introduction of PEGylation onto the original peptide . The Bmax values for BxPC-3 were twice as higher for CaSki cells, which is supported by the higher tumor uptake of radiotracers in BxPC-3 compared to CaSki tumor models.
It was observed that [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 had higher tumor uptake than [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 in both CaSki and BxPC-3 tumor-bearing mice. The tumor uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 (3.86 ± 0.58 %ID/g) in BxPC-3 tumor mouse model is slightly lower than the uptake of 4.7 ± 0.9 %ID/g achieved by [18F]FBA-(PEG28)2-A20FMDV2  and is higher that of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (2.12 ± 0.83 %ID/g), which agrees with the Bmax data. Tumor uptake was specific for all of the constructs except for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 in the CaSki tumors which is likely due to the lower expression of ανβ6 in this model. PET imaging in mice bearing BxPC-3 tumors confirmed the specific tumor targeting of both radiotracers towards integrin ανβ6 which indicates their potential as imaging agents for integrin ανβ6. However, the higher tumor uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 compared to [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 that was observed in the biodistribution studies was not seen in the PET imaging studies as the SUVs were similar at all time points. This may be due to the greater amount of mass of peptide (1–2 μg for imaging vs. 0.1–0.2 μg for biodistribution) that was injected for the imaging studies which may have partially blocked tumor uptake.
Overall, uptake in normal organs of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 was generally higher than that of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 at the earlier time points (1 and 4 h), especially in the kidney. The increased kidney uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 may be due to its +2 charge compared to the +1 charge of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2. Cationic portions of peptides may form electrostatic interactions with negative surface charge of proximal tubular cells of kidney, resulting in the trapping of the radiotracers and their metabolites in the tubular cells [32, 33]. Higher uptake in other tissues for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 and in particular the liver may be due to the higher lipophilicity of PCTA compared to DOTA. In addition, there may be expression of ανβ6 in normal organs such as the lung, kidney, muscle, and heart due to inhibition of radiolabeled peptide uptake by an excess of unlabeled peptide (Supplementary Tables 3 and 4). Previous pre-clinical studies have not investigated expression in normal organs, however, clinical evaluation of similar peptides has shown low uptake in the brain, bone, liver, and lung indicating the potential value of imaging metastases in these sites.
In conclusion, [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 and [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 bound specifically to ανβ6 on tumor cells both in vitro and in vivo. While in vivo tumor uptake [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 was superior to that of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2, the normal tissue uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 was also greater. Thus, both peptides have similar tumor to normal tissue ratios and would be equally good for imaging and therapy, which contradicts our hypothesis that [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 would be superior. Future work will focus on modifications of the peptides to improve affinity and tumor to normal tissue ratios by possibly cyclizing the peptide and substituting more hydrophilic amino acids in positions that do not adversely affect binding.
Materials and Methods
All solvents and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA) and used as received unless stated otherwise. All solutions and buffers were prepared using HPLC-grade water. Peptides were custom synthesized and characterized by AnaSpec (Fremont, CA, USA). Stock solutions of the peptides (1 nmol/μl) were prepared in HPLC-grade water and stored at −20°C before use. Non-PEGylated A20FMDV2 peptide served as blocking agent. Radio-TLCs employed Whatman 60 Å silica gel thin-layer chromatography (TLC) plates and were analyzed using a Bioscan 200 imaging scanner (Bioscan, Inc., Washington, DC, USA). Reversed-phase high-pressure liquid chromatography (HPLC) was used to evaluate the radiolabeling efficiency. HPLC utilized a two-solvent system: water (0.05% trifluoroacetic acid (TFA)) and acetonitrile (0.05% TFA). The system was equipped with UV absorbance detectors (UV, 220 and 280 nm), a NaI radiotracer detector and a photodiode array detector. HPLC analysis of peptides used Kinetex (Phenomenex) C-18 column (5 μm, 4.6 × 150 mm I.D.).
CaSki and BxPC-3 cell lines purchased from ATCC (Manassas, VA, USA) were revived from liquid nitrogen storage and cultured at 37°C, 5% CO2. The media for CaSki cells contained DMEM, 10% heat-inactivated fetal bovine serum (FBS) (Gibco), and 10 mM HEPES. The media for BxPC-3 cells contained RPMI 1640, 10% FBS, and 10 mM HEPES. Cell-labeling solutions and biodistribution samples were analyzed on a Beckman Gamma 8000 counter containing a NaI crystal (Beckman Instruments, Inc., Irvine, CA, USA).
Radiochemical synthesis of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
64Cu was produced from 64Ni(p,n)64Cu nuclear reaction on enriched 64Ni on a TR-19 biomedical cyclotron (Advanced Cyclotron Systems, Inc. - Canada) at Mallinckrodt Institute of Radiology, Washington University School of Medicine, and purified with an automated system using standard procedures [34, 35]. The resulting activity was diluted in 0.1M HCl at a specific activity ranging from 300 to 2000 mCi/μg. An aliquot of 2 μl DOTA-(PEG28)2-A20FMDV2 peptide (2 nmol) was diluted to 100 μl with 0.1M NH4OAc (pH 5.5). A stock solution of 64Cu in 0.1M HCl was diluted ten-fold with 0.1M NH4OAc (pH 5.5) for radiolabeling and 1mCi of 64Cu was added to the reaction mixture. The reaction mixture was incubated at 45°C for 1 h. The product was evaluated for radiochemical purity by radio-HPLC and TLC with a mobile phase of 50 mM DTPA. The radiolabeled complex remained at the origin in the TLC system, while the free 64Cu moved with solvent front.
The synthesis of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 was similar to [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 except that reaction solution was incubated at 80°C for 15 mins. Quality control was performed by TLC and HPLC as described above.
100 μl of human serum albumin (HSA 1g/ml) or 1X Phosphate Buffered Saline (PBS) was prepared in Eppendorf tubes, followed by the addition of 100 μl of 64Cu-radiolabeled peptides. The resulting reaction mixtures were incubated at 37°C with moderate agitation. At time points of 1, 4 and 24 h, aliquots (0.5 μl) were withdrawn from the sample and spotted on TLC plates. Radio-TLCs with a mobile phase of 50 mM diethylenetriamine pentaacetate (DTPA) was performed to evaluate the fraction of intact radiotracer at specific time points.
Wash buffer of PBS 1X, 0.1% BSA, and 0.1% sodium azide was prepared. Confluent cells were harvested and re-suspended in wash buffer. Aliquots of 3 × 105 cells in 96-well-plate were incubated with 100 μl primary Ab 10D5 (ανβ6 positive) (10 μg/mL in FACS buffer) at room temperature for 1 h, 500 rpm. After washing the cells three times with wash buffer, cells were incubated in 100 μl of Alexa Fluor 488 goat-anti-mouse (10 μg/mL diluted to 1:50 in FACS buffer) for 30 mins at room temperature. Cells were then rinsed and re-suspended in a final volume of 200 μl wash buffer. In control samples, the primary Ab 10D5 antibody was replaced by IgG2a Isotype Control (ανβ6 negative). Flow cytometric analysis was performed using a FACScan flow cytometer and data presented as mean fluorescence units (MFUs).
Cell binding and internalization
For 64Cu cell-binding experiments, a method similar to that described by Geissler et al. was used . Briefly, 3.7 KBq (0.1μCi) aliquots of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 or [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 was added to a cell suspension of either CaSki or BxPC-3 cells in PBS 1X (pH 7.4; 2.0 × 106 cells in 50 μl). Assay tubes were pretreated with 5% bovine serum albumin (5% wt/v in PBS) to block non-specific binding. Reaction mixtures were incubated at various time points (15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h) with moderate shaking to prevent cell settling. Cells were centrifuged and supernatant was aspirated from cell pellets. The pellets underwent additional washes with 0.5 mL ice-cold PBS (3 times) and the fraction of bound radioactivity was measured with a gamma counter. To determine the fraction of internalized radiotracers, cells were treated with 2 × 0.5 mL of 20 mM sodium acetate (pH 4.0) for 5 mins to remove surface-bound radioactivity. Following centrifugation, cells were washed with 0.5 mL ice-cold PBS and counted for activity. To determine the specific binding towards ανβ6, non-PEGylated peptide (20 μg) was added 10 mins before the addition of radiotracers as a blocking agent. The experiments were performed in triplicate.
Radioligand saturation binding
A cell suspension of 1.0 × 108, either CaSki or BxPC-3 cells in 5 mL PBS was prepared. The non-PEGylated peptide was prepared to 10 μg/100 μl in PBS 1X as a blocking agent. Assay tubes were pretreated with 5% bovine serum albumin (5% wt/v in PBS) to block non-specific binding. A solution of 100 μL cells (2 × 106 cells) and 100 μl of blocking or PBS were added to each assay tube, followed by a series of 64Cu-radiolabeled peptide concentrations that ranged between 5 nM and 1000 nM. Tubes were slightly agitated and placed on ice for 1 h. After incubation, tubes were centrifuged for 3 mins, and the supernatant was removed. Cell pellets were washed with ice-cold PBS three times and measured for activity on a gamma counter to determine the amount of surface-bound radioactivity. The experiments were done in triplicate in the presence and absence of a 1000-fold excess blocking agent. Saturation binding curves were generated with x-axis as the molarity of radiolabeled peptides vs. y-axis as specific binding in fmol. Curves were fitted with GraphPad Prism 9 to find the equilibrium constant (Kd) and the maximum binding capacity (Bmax).
Animals were supplied by Charles River Laboratories (Wilmington, MA, USA), and were handled in compliance with the Guidelines for Care and Use of Research Animals established by the Division of Comparative Medicine and the Animal Studies Committee of Washington University School of Medicine under protocol #20–0214. Female athymic nude mice were inoculated on the right flank with 10 × 106 CaSki or 5 × 106 BxPC-3 cells. Tumors were allowed to grow until they approached approximately 100 mm3 in volume. Radiolabeled peptides were diluted in saline to a dose of 0.37 MBq (10 μCi) per 100 μl. Animals were injected intravenously with 0.37 MBq (10 μCi) of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 or [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 peptides and sacrificed by cervical dislocation at 1, 4, and 24 h. For blocking experiments, non-PEGylated peptide (100 μg in 100 μL saline) was injected ten minutes before radiotracer. Blood, lung, liver, spleen, kidney, muscle, heart, bone, and tumor were harvested. The amount of radioactivity in each organ was determined by gamma counting, and the percent injected dose per gram of tissue (% ID/g) was calculated.
BxPC-3 cells (5 × 106) were inoculated in the right shoulder of female athymic nude mice 3–4 weeks before PET imaging sessions. All the experiments involving animals followed the Guidelines for Care and Use of Research Animals established by the Division of Comparative Medicine and the Animal Studies Committee of Washington University School of Medicine under protocol #20–0214. On the day of the experiment, mice were injected intravenously with 3.7 MBq (100 μCi) of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 or [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 peptides. Mice were imaged with CT followed by static PET scans at 1, 4, and 24 h after tracer administration on an Inveon small animal PET/CT scanner (Siemens Medical Solutions, Malvern, PA, USA). Static images were collected for 20 min and reconstructed with the maximum a posteriori (MAP) reconstruction algorithm using the Inveon Reseach Workstation image display software (Siemens). Regions of interest (ROI) were selected based on co-registered anatomical CT images, and the associated radioactivity was measured using the Inveon software. The maximum standard uptake value (SUV) was calculated as the highest regional radioactivity concentration (nCi/cc) × animal weight (g)/decay-corrected amount of injected dose (nCi).
Quantitative data were processed by Prism 9 (GraphPad Software, La Jolla, CA, USA) and expressed as Mean ± SD. Statistical analysis was performed using one-way analysis of variance and Student’s t-test. Differences at the 95% confidence level (p < 0.05) were considered statistically significant.
The authors would like to thank Nikki Fettig and Lori Strong from the Washington University Small Animal imaging facility for technical assistance in conducting biodistribution studies and Washington University cyclotron facility for supplying 64Cu. The authors wish to thank Dr. Cristian A. W. Villas Boas from Department of Radiation Oncology, Washington University for his useful suggestions and comments on the manuscript.
CONFLICTS OF INTEREST
Authors have no conflicts of interest to declare.
This research received no external funding. This work was supported by the Department of Radiation Oncology at WUSM.
3. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005; 115:339–47. https://doi.org/10.1172/JCI23183. [PubMed].
5. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, Oda Y. Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract. 2003; 199:57–64. https://doi.org/10.1078/0344-0338-00355. [PubMed].
6. Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer. 2001; 92:641–50. https://doi.org/10.1002/1097-0215(20010601)92:5<641::aid-ijc1243>3.0.co;2-p. [PubMed].
7. Thomas GJ, Nyström ML, Marshall JF. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med. 2006; 35:1–10. https://doi.org/10.1111/j.1600-0714.2005.00374.x. [PubMed].
8. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995; 108:2241–51. [PubMed].
10. Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, Weinreb PH, Fleuren GJ. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol. 2007; 212:316–24. https://doi.org/10.1002/path.2168. [PubMed].
11. Li HX, Zheng JH, Fan HX, Li HP, Gao ZX, Chen D. Expression of αvβ6 integrin and collagen fibre in oral squamous cell carcinoma: association with clinical outcomes and prognostic implications. J Oral Pathol Med. 2013; 42:547–56. https://doi.org/10.1111/jop.12044. [PubMed].
12. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, Goodman SL, Kosmahl M, Klöppel G. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004; 45:226–36. https://doi.org/10.1111/j.1365-2559.2004.01919.x. [PubMed].
13. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007; 67:5889–95. https://doi.org/10.1158/0008-5472.CAN-07-0245. [PubMed].
14. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007; 67:7833–40. https://doi.org/10.1158/0008-5472.CAN-07-1026. [PubMed].
15. Kimura RH, Teed R, Hackel BJ, Pysz MA, Chuang CZ, Sathirachinda A, Willmann JK, Gambhir SS. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res. 2012; 18:839–49. https://doi.org/10.1158/1078-0432.CCR-11-1116. [PubMed].
16. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem. 1999; 274:1979–85. https://doi.org/10.1074/jbc.274.4.1979. [PubMed].
17. Liu H, Wu Y, Wang F, Liu Z. Molecular imaging of integrin αvβ6 expression in living subjects. Am J Nucl Med Mol Imaging. 2014; 4:333–45. [PubMed].
18. Hausner SH, Marik J, Gagnon MK, Sutcliffe JL. In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-"click" chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides. J Med Chem. 2008; 51:5901–4. https://doi.org/10.1021/jm800608s. [PubMed].
19. Hausner SH, Carpenter RD, Bauer N, Sutcliffe JL. Evaluation of an integrin αvβ6-specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry. Nucl Med Biol. 2013; 40:233–39. https://doi.org/10.1016/j.nucmedbio.2012.10.007. [PubMed].
20. Hausner SH, Bauer N, Sutcliffe JL. In vitro and in vivo evaluation of the effects of aluminum [18F]fluoride radiolabeling on an integrin αvβ6-specific peptide. Nucl Med Biol. 2014; 41:43–50. https://doi.org/10.1016/j.nucmedbio.2013.09.009. [PubMed].
21. Cardle II, Jensen MC, Pun SH, Sellers DL. Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting. J Biol Chem. 2021; 296:100657. https://doi.org/10.1016/j.jbc.2021.100657. [PubMed].
22. Hung KY, Harris PWR, Desai A, Marshall JF, Brimble MA. Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality. Eur J Med Chem. 2017; 136:154–64. https://doi.org/10.1016/j.ejmech.2017.05.008. [PubMed].
23. Hausner SH, Bauer N, Hu LY, Knight LM, Sutcliffe JL. The Effect of Bi-Terminal PEGylation of an Integrin αvβ6-Targeted 18F Peptide on Pharmacokinetics and Tumor Uptake. J Nucl Med. 2015; 56:784–90. https://doi.org/10.2967/jnumed.114.150680. [PubMed].
24. Hausner SH, Bold RJ, Cheuy LY, Chew HK, Daly ME, Davis RA, Foster CC, Kim EJ, Sutcliffe JL. Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma. Clin Cancer Res. 2019; 25:1206–15. https://doi.org/10.1158/1078-0432.CCR-18-2665. [PubMed].
25. Hu LY, Bauer N, Knight LM, Li Z, Liu S, Anderson CJ, Conti PS, Sutcliffe JL. Characterization and evaluation of (64)Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ 6. Mol Imaging Biol. 2014; 16:567–77. https://doi.org/10.1007/s11307-013-0717-9. [PubMed].
26. Hausner SH, Kukis DL, Gagnon MK, Stanecki CE, Ferdani R, Marshall JF, Anderson CJ, Sutcliffe JL. Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide. Mol Imaging. 2009; 8:111–21. https://doi.org/10.2310/7290.2009.00015. [PubMed].
27. Ferreira CL, Yapp DT, Lamsa E, Gleave M, Bensimon C, Jurek P, Kiefer GE. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nucl Med Biol. 2008; 35:875–82. https://doi.org/10.1016/j.nucmedbio.2008.09.001. [PubMed].
28. Yapp DT, Ferreira CL, Gill RK, Boros E, Wong MQ, Mandel D, Jurek P, Kiefer GE. Imaging tumor vasculature noninvasively with positron emission tomography and RGD peptides labeled with copper 64 using the bifunctonal chelates DOTA, oxo-DO3a. and PCTA. Mol Imaging. 2013; 12:263–72. https://doi.org/10.2310/7290.2012.00044. [PubMed].
29. Ait-Mohand S, Fournier P, Dumulon-Perreault V, Kiefer GE, Jurek P, Ferreira CL, Bénard F, Guérin B. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem. 2011; 22:1729–35. https://doi.org/10.1021/bc2002665. [PubMed].
30. Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, Mease RC, Pomper MG. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014; 57:2657–69. https://doi.org/10.1021/jm401921j. [PubMed].
31. Saha A, Ellison D, Thomas GJ, Vallath S, Mather SJ, Hart IR, Marshall JF. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol. 2010; 222:52–63. https://doi.org/10.1002/path.2745. [PubMed].
32. Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008; 60:1319–28. https://doi.org/10.1016/j.addr.2008.04.005. [PubMed].
33. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med. 2001; 28:1725–35. https://doi.org/10.1007/s002590100570. [PubMed].
34. Kume M, Carey PC, Gaehle G, Madrid E, Voller T, Margenau W, Welch MJ, Lapi SE. A semi-automated system for the routine production of copper-64. Appl Radiat Isot. 2012; 70:1803–6. https://doi.org/10.1016/j.apradiso.2012.03.009. [PubMed].
35. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, Anderson CJ, Welch MJ. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997; 24:35–43. https://doi.org/10.1016/s0969-8051(96)00157-6. [PubMed].
36. Geissler F, Anderson SK, Venkatesan P, Press O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 1992; 52:2907–15. [PubMed].
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.